Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing

Pharmacol Ther. 2020 Dec:216:107706. doi: 10.1016/j.pharmthera.2020.107706. Epub 2020 Oct 16.

Abstract

Artemisinins are a unique class of antimalarial drugs with significant potential for drug repurposing for a wide range of diseases including cancer. Cancer is a leading cause of death globally and the majority of cancer related deaths occur in Low and Middle Income Countries (LMICs) where conventional treatment options are often limited by financial cost. Drug repurposing can significantly shorten new therapeutic discovery pathways, ensuring greater accessibility and affordability globally. Artemisinins have an excellent safety and tolerability profile as well as being affordable for deployment in Low and Middle Class Income Countries at around USD1 per daily dose. Robust, well designed clinical trials of artemisinin drug repurposing are indicated for a variety of different cancers and treatment settings.

Keywords: Anti-cancer therapy; Artemisinins; Artesunate; Cancer; Drug repurposing; Oncology.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antimalarials / adverse effects
  • Antimalarials / therapeutic use*
  • Antineoplastic Agents, Phytogenic / adverse effects
  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Artemisinins / adverse effects
  • Artemisinins / therapeutic use*
  • Drug Repositioning*
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / epidemiology
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Signal Transduction
  • Translational Research, Biomedical

Substances

  • Antimalarials
  • Antineoplastic Agents, Phytogenic
  • Artemisinins